Tag: GlaxoSmithKline

  • GlaxoSmithKline’s exit and the Nigerian blame game

    GlaxoSmithKline’s exit and the Nigerian blame game

    By Ashimi Jamiu Adewale

    I have followed the ongoing debate on the exit of GlaxoSmithKline company from Nigeria and the attempts to blame an administration that is less than eight months for the exit of the company.

    Background

    In order to have a proper understanding of my perspective on this issue, I need to provide a background so that the issues at stake will be well understood.

    The white race is a very adventurous and enterprising race. The economic relationship between them and us in Africa was established firmly at a stage they needed raw materials for their industries.

    They established a system of governance and provided infrastructures to extract and transport the raw materials to their industries.

    In exchange, they sold finished products to us. They established companies like Glaxosmithkline to distribute their products in the country.

    We sell cocoa to industries in the western countries and they use it to produce several finished products, Bournvita, Ovaltine, Milo, several chocolates etc. Thus, an unequal economic relationship was established.

    This relationship was sustained for many years, but rapid urbanisation led to more and more demands for finished products from these countries.  The situation encouraged big multinational companies to establish companies in the country to market their products in Nigeria. In some cases, it was convenient for them to establish industries to assemble their products here for distribution.

    Read Also; Our transformation efforts on economy succeeding with NASS cooperation – Tinubu

    The impact of this unequal economic relationship started being felt in the early 1980s. We initially resorted to taking loans at very exploitative conditions so that we can continue to buy finished products for our use. However, repayments became a problem because the raw materials we sold could not pay for imported items and service loans. So we could not import enough to meet our needs, hence we resorted to rationing. This gave rise to the era of queuing for essential commodities and the attendant hardships.

    To eliminate queuing for essential commodities, the foreign exchange market mechanism was introduced by the experts from the World Bank.

    The way it works is that if we have Nigerians demanding foreign products to the tune of N2 million and we have $1 million in the market; the exchange rate would be N2 to $1. However, because our demand continued to increase, it became N200 million to $1 million. The exchange rate became N200 to $1. Today, it is over N1000 to $1.

    The implication of this steady decline in the purchasing power of the naira is the reduction in standard of living in Nigeria, inability of the import oriented multinational companies to expand and create jobs, massive unemployment and brain drain of our skilled manpower. The rapid decline in purchasing power led to a situation where so many people could not purchase expensive items but look for cheap products.

    Where industries transform raw materials into finished products, there are, usually, massive investments in research. The research activities lead to the creation of new products, and the establishment of more industries. Even when some companies are closing down, new ones are being created to provide better services. These types of opportunities are lacking in countries where multinational companies only engage in the distribution of finished products or assemblies and distribution of products.

     Exit of GlaxoSmithKline and other companies

    The major reason for the exit of GlaxoSmithKline Company and others is not because of the policies of a government that is less than eight months old. Rather, the companies leaving are reacting to unfavourable situations in the very competitive international market. In a situation where several companies from other countries now sell similar products at relatively cheaper prices in the same Nigerian market, the consumers are rational, and they will prefer to pay less to get the same service.

    The mistake, therefore, was made by these companies. They should have invested massively in research activities in our universities to develop more new and better products, continuously establish new companies and employ more Nigerians (because the cost of labour in Nigeria is several times less than what they pay their countrymen). This strategy would have made it possible for them to produce at globally competitive prices. It would have been difficult for competitors from other countries to drive them out of Nigeria. They would have created jobs for our youths, reduce unemployment and poverty.

    However, we Nigerians are also to be blamed because we did not provide the critical infrastructures such as electricity and effective transportation network and enabling environment to attract genuine investors who could invest in research; use our raw materials to produce finished goods for our internal consumption and possible export of excess products.

    If they had done that, they would not be folding up due to competition from other foreign companies.

    Way forward

    Given this background, the government should focus more on provision of infrastructures and creating an investment-friendly environment for companies that are interested in investing in research and processing our raw materials into finished products for internal consumption and export. These are the lessons we should all learn from their exit.

    • Adewale is a retired Permanent Secretary, Lagos State.

  • NSE trading reopens on depressed note

    NSE trading reopens on depressed note

    Weekly transactions on the Nigerian Stock Exchange ( NSE ) opened on Monday on depressed note with the market indices sliding by 0.90 per cent.

    According to our reporter, the market capitalisation shed N136 billion or 0.90 per cent to close at N15.337 trillion amidst profit taking.

    It closed at N15.476 trillion on Friday.

    Also, the All-Share Index, which opened at 43,127.92, lost 390.03 points or 0.90 per cent to close at 42,737.89.

    An analysis of the price movement table indicated that Dangote Cement led the gainers’ table gaining N5.30 to close at N272 per share.

    Betaglass followed with a gain of N3.25 to close at N68.70, while PZ Industries gained N1.40 to close at N25.40 per share.

    International Breweries appreciated by N1 to close at N60, while GlaxosmithKline also added N1 to close at N21.20 per share.

    Conversely, Nigerian Breweries recorded the highest loss, dropping by N3.90 to close at N133 per share.

    Read Also: NSE tightens control on block divestment, large trades

    Guaranty Trust Bank trailed with N2.40 to close at N45.60, while Lafarge Wapco was down by N2 to close at N50 per share.

    Zenith International Bank shed N1.50 to close at N29.40, while Flour Mills depreciated by N1.10 to close at N31.50 per share.

    Similarly, the volume of shares traded closed lower as investors exchanged 517.44 million shares worth N5.19 billion in 5,852 deals.

    This was in contrast to the 552.39 million shares valued at N4.49 billion shares traded in 5,489 deals on Friday.

    Skye Bank was the investors’ delight accounting for 73.15 million shares worth N79.16 million.

    It was followed by FBN Holdings with 71.34 million shares worth N815.73 million, while Jaiz Bank traded 40.57 million shares valued at N42.39 million.

    Transcorp sold 40.48 million shares worth N84.07 million, while FCMB Group traded 26.22 million shares valued at N71.33 million.

    NAN

     

  • Brooks+Blake wins 4th consecutive MWA PR laurel

    Brooks+Blake wins 4th consecutive MWA PR laurel

    Perception management outfit, Brooks and Blake Nigeria has won the Marketing World Awards (MWA) as the best Public Relations agency in Nigeria for the fourth year running at the 7th edition held at the Kempinski Ambassador Hotel Accra, Ghana.

    The Awards organised by Instinct Wave media recognises outstanding personalities and organisations in the marketing communication industry in Nigeria and West Africa.

    Speaking at the awards, Group Executive Publisher, Marketing World Magazine Mr. Akin Naphtal commended all nominees at the awards and promised to continue to beam the searchlight of the awards on excellence in the marketing communication field.

    “The Marketing World Award is an annual event held to celebrate and reward organisation and individuals that have delivered superior product values to the market and exhibited excellence in upholding concrete marketing strategies.

    “This year, we have chosen to identify professionalism, diligence, consistency and innovation across West Africa. The process of selection for this award was done by professionals and veterans who have developed certain indices as criteria for selection as obtainable across the world. What we are celebrating today is the can do spirit of Nigerian companies and we are proud we have them in abundance,” Naphtal said.

    In his reaction, the Principal Partner, Brooks and Blake Nigeria Limited, Mr. Sola Fijabi said his organisation is honoured to have won the award for the fourth time in a row.

    “Winning the Marketing World Award for four consecutive years is quite heartwarming. We thank all our clients who believe in us. We have been able to come this far because we are working for them.

    “Our promise is to continue being the company we are, creating new frontiers for excellence in the industry, collaborating with our colleagues to make the industry the pride of everyone, which will in turn continue to engender respect for the profession and the value it brings to the marketing communication practice,” said Fijabi.

    Some of the clients of Brooks+Blake include multinational companies like MTN Nigeria, GlaxoSmithkline Consumer and Pharmaceuticals Nigeria Plc, Unilever Nigeria Plc, and Suntory Food and Beverages.

     

    Also speaking on the recognition, the Executive Director, Brooks and Blake, Taiwo Ogunwumi, reiterated the firm’s commitment to continually maintain its exceptional delivery of service to its clients as a way to uphold the tenets of the award.

     

    “Winning consecutively for four years validates the fact that devotion and immense commitment to the clients’ needs with a clearly defined vision has its incentives. We are delighted with this experience as it indicates that we have been doing our job right and contributing our own little quota to promote the healthy growth of the marketing industry. We dedicate this award to the Brooks and Blake family and all our clients. We are thankful for the trust they put in us and it is because of them that we are constantly recognized for scaling the heights and adding value” Ogunwumi said.
    It would be recalled that Brooks and Blake earlier this year also clinched the Marketing Edge Award for the 2017 PR Agency of the year.

  • GlaxoSmithKline focuses on consumer healthcare products

    Nigeria’s healthcare  consumer company,GlaxoSmithKline, said it will concentrate its efforts in broadening its range of health-care products. It also said it will widen the distribution of its products to boost sales.

    The company said it is taking the step to cushion the impact of its depleted revenue arising from the challenging economy last year and the disposal of its drinks business which also resulted in a cut of its intake.

    GlaxoSmithKline said in a statement that it will now focus on its Over The Counter (OTC), Oral Health care and pharmaceutical business with the aim of driving improved margins and sustainable growth in Nigeria. Profit after tax for the year 2016 of N4.2billion represented a 335 per cent growth compared to 2015 on the back of profits from the divested drinks business of N1.8billion and N2.4billion  (including the effect of tax credit) from continuing operations,  although turnover was 21 per cent lower than 2015, the company said in a statement.

     

  • GlaxoSmithKline appoints new MD Pharma, Bhushan

    GlaxoSmithKline appoints new MD Pharma, Bhushan

    GlaxoSmithKline (GSK) has announced the appointment of Bhushan Akshikar as its Managing Director, Pharmaceuticals Nigeria Limited.

    Bhushan joined the Nigeria business in January 2017 from Mumbai, India, where he held the position of Executive Vice President, GlaxoSmithKline India.

    He will be part of a wider Africa and Developing Countries Leadership team, responsible for driving business performance and top line growth in Nigeria. 

    Prior to joining GSK, Bhushan worked with Johnson & Johnson for over 16 years across diverse markets like India, South Korea and Belgium.

    He holds a post graduate MBA in Marketing and a Bachelor’s Degree in Pharmaceutical Sciences from the University of Mumbai, India.

    With over two decades of working in varying positions and increasing responsibility in the healthcare industry, Bhushan brings rich and broad commercial experience to the GSK Nigeria business.

  • GlaxoSmithKline appoints media, govt communication director

    GlaxoSmithKline appoints media, govt communication director

    GlaxoSmithKline, a science-led global healthcare company, has announced the appointment of Omongiade Ehighebolo as its new Communications & Government Affairs Director (Pharmaceuticals) for West and Central Africa.
    Omongiade, who joined the business in February 2017, will be responsible for strengthening and executing GSK Pharmaceutical’s overall strategic Communications and Government Relations plans. He will use his deep understanding of the environment to enhance the company’s external stakeholder engagement portfolio with the aim of strengthening the healthcare infrastructure in Nigeria.

    Ehighebolo joins GSK Pharma from Procter & Gamble, where he worked in different capacities since 2005. He brings a wealth of valuable experience spanning Communications & Government Affairs, Regulatory and Manufacturing Systems in Nigeria and across Sub-Saharan Africa.

    His last role saw him responsible for Regional Regulatory, Communications and Government Relations for Procter & Gamble (P&G) Greater West Africa Operations.

    A graduate of Mechanical Engineering from the University of Benin, Omon brings vast knowledge and experience to the Pharmaceutical business in Nigeria and is considered an asset to the GSK Pharmaceuticals Leadership team.

  • GlaxoSmithKline shares up as profits beat forecasts

    GlaxoSmithKline’s shares rose  four per cent after its third-quarter results beat expectations and it pledged to return an additional £4bn to shareholders via a special share scheme.

    The UK pharmaceuticals giant reported a pre-tax profit of £548m for the three months to the end of September, sharply down from £1.4bn a year ago.

    But the results beat analyst forecasts.

    Hargreaves Lansdown’s head of equities, Richard Hunter, said the results could prove “a turning point”.

    “The drive towards containing costs is also in evidence, whilst the company anticipates significant savings as a result of the restructure. In the medium to long term, Glaxo is also predicting a potentially lucrative pipeline, which should underpin prospects,” he added.

    GlaxoSmithKline’s shares have tumbled 14 per cent over the past three months, compared with a five per cent fall for the FTSE 100 over the same period.

    The business has been rocked by allegations of bribery in China, requiring it to pay a fine of nearly $500m, as well as patent expiries.

    A downward turn in its US business, due to pricing pressure on its key asthma drug Advair, and the impact of the strong pound on overseas profits have also weighed on the shares.

    However, GSK said it was now targeting £1bn of annual cost savings over the next three years aimed at “refocusing” the business.

    It also said it would explore a possible flotation of ViiV Healthcare, a division focusing on treatment for HIV, to “enhance visibility within the group”.

    The firm also reiterated its financial outlook for the full year, saying core earnings would be “broadly similar to 2013”.

    “We have continued to make strategic choices to create value from assets held in the group and to respond to the pressures we are facing in our operating environment,” said GSK chief executive Andrew Witty.

  • Osunkeye retires from GlaxoSmithKline Consumer

    •Board changes raise concerns

    Chief Olusegun Osunkeye will be retiring as the chairman of GlaxoSmithKline Consumer Nigeria (GSK Nigeria) Plc next month, The Nation has learnt.

    Osunkeye, who is due for re-election at the forthcoming annual general meeting (AGM) of the company in June, has decided not to seek re-election and rather retire from the board of healthcare company, after serving for 14 years as the chairman of board of directors.

    Impeccable source indicated that the decision is a voluntary decision as Osunkeye had earlier retired from similar position on the board of Nestle Nigeria, citing the need to scale down his active corporate involvements. But the massive changes on the board of directors since the botched attempt by GlaxoSmithKline United Kingdom to increase its majority equity stake in GSK Nigeria have fuelled concerns that the changes might not be unconnected with the failed acquisition bid.

    Osunkeye, who holds the largest equity stake in GSK Nigeria, who is widely regarded as the most iconic corporate leader in Nigeria, received standing ovation and loud celebration from minority shareholders at his final AGM in Nestle Nigeria. The June AGM will also be his last AGM at GSK Nigeria. He however still shares the board of Lafarge Cement Wapco Nigeria Plc.

    Over 14 years as chairman of GSK Nigeria, Osunkeye led many changes and growth plans to firmly establish GSK as the leader in the healthcare sector. He was appointed as chairman in February 2000.

    Performance review showed that GSK’s turnover has risen from N2.6 billion in 2000 to close 2013 at N29.2 billion. While profit before tax was a modest N97 million in 2000, the audited report for 2013 indicated pre-tax profit of N4.3 billion. There have also been significant investments in the company’s operations in Nigeria with investments in fixed assets at N12.1 billion in 2013 as against N424 million in 2000.

    Osunkeye led the expansion of the company’s production facilities, which enabled the company to produce most of its leading brands such as Macleans, Panadol, Lucozade Boost, Ribena and Horlicks from its Agbara, Ogun State factory.

    The Osunkeye-led board was, however, unable to push through a vexatious bid by GSK UK to acquire additional 28.58 per cent equity stake from Nigerian shareholders to push its majority equity stake to 75 per cent. Since the July, last year forced withdrawal of the acquisition bid, most directors on the board have either resigned or retired.

    Alongside Osunkeye, Mansur Ahmed, who is also due for re-election at the June AGM, has opted not to seek re-election and will be retiring with Osunkeye.

    Earlier, Mr. Chidi Okoro, the Nigerian Managing Director of GSK Nigeria, had resigned in March, this year. GSK has not appointed a replacement; rather it announced that Mr Justin Korte, a South African who was appointed to the board as director and general manager in January, this year, will preside over the management.

    Besides, three other directors resigned and were replaced after the July, last year botched acquisition bid. These included Mr. Sameer Goel, Mr. Simon Hodge and Mr. Andries Van Rooijen.

    GSK UK, which held majority equity stake of 46.4 per cent in GSK Nigeria through two wholly- owned subsidiaries, had pushed to acquire 273.46 million ordinary shares out of the Nigerian shareholders’ holdings to add 28.58 per cent and push its post-acquisition holding to 75 per cent. It proposed a price of N48 per share.

    According to the proposal, GSK UK sought to acquire additional shares of GSK Nigeria on a pro rata basis from existing shareholders through a Scheme of Arrangement, implying that the proportionate percentage will be deducted from all Nigerian shareholders and added to GSK UK.

    The deal was rejected by Nigerian shareholders despite of several assurances and promises of more investments in the Nigerian operations by GSK UK. While GSK UK had indicated it would use its current 46.4 per cent equity stake as a block vote in support of the deal and the board of the GSK Nigeria also recommended the deal, minority and retail shareholders piled up pressures on capital market regulator, Securities and Exchange Commission (SEC), which also reviewed its earlier approval for the deal.

    Impeccable market sources had said GSK UK was taken aback by the overwhelming rejection of the acquisition bid, which it had hinged on its consideration for new significant investment in the Nigerian subsidiary.

    Osunkeye had told the scheduled court-ordered meeting in Lagos that GSK decided to step down the acquisition bid to consider appropriate amendments that will make the offer more acceptable to shareholders.

    “We withdrew in order to further consultations, we believe further consultations and arrangements are necessary before we come back,” Osunkeye said. But the scheme for the bid has not resurfaced since.